Company / Working Capital
Taysha Gene Therapies, Inc. Working Capital History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$298.1M
FY2025
5-year range
$33.6M / $298.1M
FY2021-FY2025
Trend
+157.2%
vs FY2024
Sector context
#142 of 213
Health Care
What the data says
At $298M, Taysha Gene Therapies, Inc.'s working capital ranks #142 of 213 in the Health Care sector. Working Capital has increased for 3 consecutive years, from $34M in FY2022 to $298M in FY2025.
Based on SEC 10-K filings.
$298M in FY2025 with a 5-year CAGR of +3.5%.
Improved from $113M to $298M over the past 2 years.
Health Care sector context is included.
Working Capital over time
Growth rates
- 3-Year CAGR
- +107.0%
- 5-Year CAGR
- +3.5%
- 10-Year CAGR
- -
Sector benchmark
#142 of 213 in Health CareTop 67% of 213This company $298.1M Sector average $934.6M
▼
-68.1% below sector average
Key checks
Key Insights
- Taysha Gene Therapies, Inc.'s working capital has grown for 3 consecutive years.
- 5-year CAGR of +3.5%, indicating consistent growth.
- In FY2025, working capital increased 157.2% year-over-year.
- Ranks #142 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -1.03 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $298.1M | +157.2% |
| FY2024 | $115.9M | +2.5% |
| FY2023 | $113.1M | +236.4% |
| FY2022 | $33.6M | -68.8% |
| FY2021 | $107.9M | -57.0% |
| FY2020 | $250.8M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026